CA2834286A1 - Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders - Google Patents

Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders Download PDF

Info

Publication number
CA2834286A1
CA2834286A1 CA2834286A CA2834286A CA2834286A1 CA 2834286 A1 CA2834286 A1 CA 2834286A1 CA 2834286 A CA2834286 A CA 2834286A CA 2834286 A CA2834286 A CA 2834286A CA 2834286 A1 CA2834286 A1 CA 2834286A1
Authority
CA
Canada
Prior art keywords
4alkyl
phenyl
group
4alkenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2834286A
Other languages
English (en)
French (fr)
Inventor
Joseph Moskal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of CA2834286A1 publication Critical patent/CA2834286A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2834286A 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders Abandoned CA2834286A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US61/479,593 2011-04-27
US201161527744P 2011-08-26 2011-08-26
US61/527,744 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Publications (1)

Publication Number Publication Date
CA2834286A1 true CA2834286A1 (en) 2012-11-01

Family

ID=47073094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2834286A Abandoned CA2834286A1 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders

Country Status (13)

Country Link
US (4) US20140107037A1 (enExample)
EP (2) EP2701721A4 (enExample)
JP (1) JP6035326B2 (enExample)
KR (5) KR20200043534A (enExample)
CN (2) CN103974712A (enExample)
AU (1) AU2012249397B2 (enExample)
BR (1) BR112013027554A2 (enExample)
CA (1) CA2834286A1 (enExample)
EA (2) EA029999B1 (enExample)
HK (1) HK1258231A1 (enExample)
MX (1) MX357761B (enExample)
SG (2) SG10202010665YA (enExample)
WO (1) WO2012149389A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
WO2011100585A1 (en) 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
PE20151416A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
US9758525B2 (en) 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9745342B2 (en) * 2013-10-28 2017-08-29 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
CN111920412A (zh) * 2013-12-13 2020-11-13 西北大学 治疗脑部病症或鉴定与其相关的生物标记的方法
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
AU2015280108B2 (en) * 2014-06-23 2019-11-28 Naurex, Inc. Methods of treating or ameliorating migraine
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR102465758B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
WO2009105718A1 (en) * 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases

Also Published As

Publication number Publication date
WO2012149389A3 (en) 2014-05-08
US20190209642A1 (en) 2019-07-11
EA029999B1 (ru) 2018-06-29
HK1258231A1 (zh) 2019-11-08
KR20190037359A (ko) 2019-04-05
KR20140043078A (ko) 2014-04-08
EA201391581A1 (ru) 2014-05-30
AU2012249397B2 (en) 2017-03-30
SG10202010665YA (en) 2020-11-27
EP2701721A4 (en) 2015-12-16
CN108283712A (zh) 2018-07-17
KR20210046843A (ko) 2021-04-28
JP2014520072A (ja) 2014-08-21
EP3679931A3 (en) 2020-10-14
US20140107037A1 (en) 2014-04-17
KR20180095096A (ko) 2018-08-24
WO2012149389A2 (en) 2012-11-01
US20210169964A1 (en) 2021-06-10
SG194230A1 (en) 2013-12-30
KR20200043534A (ko) 2020-04-27
JP6035326B2 (ja) 2016-11-30
EA201790653A1 (ru) 2017-07-31
US20170049845A1 (en) 2017-02-23
MX357761B (es) 2018-07-23
MX2013012526A (es) 2014-04-16
CN103974712A (zh) 2014-08-06
EP3679931A2 (en) 2020-07-15
BR112013027554A2 (pt) 2016-09-06
AU2012249397A1 (en) 2013-11-07
EP2701721A2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
CA2834286A1 (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
JP2014520072A5 (enExample)
CA3019663C (en) IVACAFTOR ANALOGUES CONTAINING SILICONE ATOMS
KR102391134B1 (ko) 벤조퀴놀린 화합물을 제조하는 방법
CA2992211C (en) Prodrugs of fumarates and their use in treating various diseases
JP4511023B2 (ja) 神経細胞ニコチン性α７レセプタアゴニストとしてのベンジリデン−およびシンナミリデン−アナバセイン
JP2013544277A5 (enExample)
UA109802C2 (xx) Похідні біцикло$3.2.1]октиламіду та їх застосування
AU2014212465A1 (en) S1P modulating agents
EP2938616A1 (en) The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
PH12015501145A1 (en) Peptides as oxytocin agonists
JP2010024243A (ja) 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体
JP2018534300A5 (enExample)
AU608692B2 (en) Tetrazole excitatory amino acid receptor antagonists
US12227479B2 (en) Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury
WO2013157511A1 (ja) アリールアミノピラゾール誘導体
DD279674A5 (de) Verfahren zur herstellung von hydrierten 1-benzooxacycloalkyl-pyridincarbonsaeureverbindungen
CN112839929A (zh) Tlr8 激动剂
HRP20110093T1 (hr) Kristalna baza escitaloprama i orodisperzibilne tablete koje sadrže bazu escitaloprama
JP2010527958A (ja) Ｓ１ｐ受容体モジュレーターとして有用なベンズアミド
CN1230959A (zh) N－(2－苯并噻唑基)－1－哌啶乙胺衍生物,其制备方法及其在治疗中的应用
JP2013529687A5 (enExample)
AU2011280031A1 (en) Synthesis and use of Kinase inhibitors
WO2022060944A1 (en) Compositions for modulating splicing
WO2022010882A1 (en) Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170131

FZDE Discontinued

Effective date: 20220512